Management of Chylous Ascites with Octreotide in a Bangladeshi Child: A Case Report

MOHAMMED NURULLAH¹, A S M BAZLUL KARIM², MD. RUKUNUZZAMAN³, MD. WAHIDUZZAMAN MAZUMDER⁴, FAHMIDA BEGUM⁵

Introduction
Congenital chylous ascites (CCA) is a rare disease that results from mal-development of the intra-abdominal lymphatic system; characterized by accumulation of chylomicron-rich lymphatic fluid in the peritoneal cavity.¹ The etiological factors of abdominal chylous ascites glycemic in the pediatric population can be primary or secondary. Abnormalities connected with the development and maturation of lymphatic vessels are the cause of the primary process.²,³ Dysplastic lymphatic vessels, both hypo- and hyperplastic ones favor lymphatic leak-age in the mechanism of increasing pressure in the lymphatic system, resulting lymphatic congestion.⁴,⁵ Delayed maturation of lymphatic vessels leading to abnormal structure of their walls, also results in lymphatic leakage to the peritoneal cavity. Developmental disorders of lymphatic vessels constitute the main cause of congenital chylous ascites found in newborns. The use of somatostatin and its analogue (octreotide) has recently been introduced into the management of iatrogenic chylothorax and chyloperitoneum in children.⁶,⁷ Probable mechanisms of action include decrease in lymph production and its flow rate. Octreotide has become popular drug for the treatment of chylous ascites because of its ease in administration, low invasiveness, short treatment time and its high effectiveness.⁸ Here, we report a case of CCA in a child successfully treated with octreotide.

Case report
Omor Bin, a 5 year old boy only issue of his non-consanguineous parents admitted with the complaints of abdominal distension since birth. He was diagnosed as a case of congenital cystic hygroma from antenatal ultrasonography (USG) and operated twice, one at 1½ months and another at 3 year of his age by a pediatric surgeon and also treated with sclerotherapy by local injection of sclerogent agent (Ethanolamine-N-Olate). However, his condition did not improve rather he had persistent ascites as shown by serial USG. He was mildly pale, non-icteric and vitals were within normal limit. Per abdominal examination showed abdominal distention with fullness of flanks and transverse umbilical slit. There were two scar marks, one at left lower abdomen and another at left lower back. He had no organomegaly but had ascites. The case was investigated and his ascetic fluid was milky white and triglyceride of ascetic fluid was 1718 mg/dl. Octreotide was started, (Sandostatin; Novartis Pharmaceuticals China Ltd) in continuous intravenous infusion at a rate of 0.5 ìg/kg/h and gradually increased to 1.0ìg/kg/h on day 3 of treatment and continued till 7 days and then tapered and discontinued on day 10.

Fig-1: Doses of Octreotide.
Twenty-four hours after starting octreotide, abdominal girth started decreasing. His abdominal girth decreased from 61 cm to 53 cm after completion of octreotide. Follow up USG shows no ascites. No side effects of octreotide, such as diarrhea, hypoglycemia or hyperglycemia, hypotension or liver dysfunction (including cholestasis) were noted throughout the whole treatment period.

Treatment options for chylous ascites are conservative and surgical. Conservative treatment is usually MCT based died with somatostatin analogue and surgical options are reductive surgery and sclerotherapy. Surgery is usually indicated after failure of conservative treatment. Surgery is an invasive procedure and requires expertise and is associated with significant morbidity and mortality. However, such procedure is limited by anatomic variations of the duct location, as well as difficulty to identify the leaking site. In this present case, surgery was done twice and sclerotherapy once. Therefore, it is apparent that a pharmacologic agent that augments closure of the leak would be very valuable in the treatment of chylous effusion. Karagoz et al. developed their own treatment scheme, according to which the therapy should begin with a few weeks of enteral nutrition with a diet including fat emulsion in the form of MCT. Next, enteral nutrition should be withheld and parenteral nutrition should be started with administration of somatostatin. The last stage is the surgery. Octreotide was first reported to significantly reduce chylous effusion in an adult with chylothorax and subsequently in several other patients with various etiologies.

Octreotide is a somatostatin analogue that inhibits the secretion of some pituitary and gastrointestinal hormones, reduce secretion of fluids from the intestine and pancreas, causes vasoconstriction in the blood vessels and increases splanchnic arteriolar resistance, reducing gastrointestinal flow and consequently the lymph flow. It is a pharmacologic agent that also augments the closure of any leakage in the lymphatic system.

There are a few case reports in literature that use octreotide successfully to reduce chylous ascites. There are age and etiology variation. In addition, variations regarding octreotide dosing regimens (0.5–8 mcg/kg/h), modes of drug administration (intravenous or subcutaneous), commencement and duration of treatment have been reported in the literature.

We used octreotide by intravenous infusion at a rate of 0.5 mcg/kg/h and gradually increased to 1 mcg/kg/h on day 3 and continued till day 7 then tapered and discontinued on day 10. Huang et al. also used same dose and duration. A dramatic decrease in chyle production was observed within 24 hours of infusion, with complete resolution of ascites by 10
days after treatment. Given the observed rapid resolution of chylous effusion concurrently with the octreotide administration, it appears that octreotide infusion rather than natural healing was responsible for the closure of chyle leakage and that is very promising.

It has some adverse effects like nausea, diarrhea, fatty stools, transient abdominal distension, liver dysfunction and transient glucose disturbance reported in pediatric population. In our case we followed up the patient blood pressure, capillary blood glucose but there were no significant adverse effects. Therefore, it can be said that a relatively low dose of 0.5-1.0μg/kg/h of infusion seems to be sufficient for satisfactory outcome with minimal side effects.

Conclusion
The result found from the present study is encouraging with respect to drug safety and favorable outcome for the treatment of chylous ascites. We suggest that octreotide may be considered as an effective therapeutic option for management of pediatric chylous ascites.

Message
Medical management of chylous ascites with octreotide may be tried in unresponsive cases.

References